A PHASE 2A, DOUBLE-BLIND, PLACEBOCONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF IRL201104 IN ADULT PARTICIPANTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS (EOE)
Clinical Trial Grant
Administered By
Medicine, Gastroenterology
Awarded By
Revolo Biotherapeutics
Start Date
January 25, 2022
End Date
June 30, 2023
Administered By
Medicine, Gastroenterology
Awarded By
Revolo Biotherapeutics
Start Date
January 25, 2022
End Date
June 30, 2023